Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma

22 Nov 2013

Abstract excerpt

Since the early 1990s, the synthesis and subsequent clinical application of small molecule inhibitors of the ubiquitin proteasome pathway (UPP) has revolutionized the treatment and prognosis of multiple myeloma. In this review, we summarize important aspects of the biology of the UPP with a focus on its structure and key upstream/downstream regulatory components. We then review current knowledge of plasma cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Peptidase Inhibition and Analysis
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24261677
DOI: 10.3109/10428194.2013.828351

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myelomaPMID 24261677Read ↗

Emerging therapies targeting the ubiquitin proteasome system in cancerSemantic proximity Read ↗

Proteasome-associated deubiquitinases and cancerSemantic proximity Read ↗

Molecular mechanisms in multiple myeloma drug resistance.Semantic proximity Read ↗

The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple MyelomaSemantic proximity Read ↗

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity Read ↗

The Tao of myeloma.Semantic proximity Read ↗

CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagySemantic proximity Read ↗

Current Review on High-Risk Multiple Myeloma.Semantic proximity Read ↗

Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.Semantic proximity Read ↗

Primary plasma cell leukemia 2.0: advances in biology and clinical management.Semantic proximity Read ↗

Updates to the drug‐resistant mechanism of proteasome inhibitors in multiple myelomaSemantic proximity Read ↗

Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.